Clinical Trial Update: Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871 [Phase 2]

View source ↗

Summary

Phase 2 trial of inhaled AZD8871 in chronic obstructive pulmonary disease completed with posted results evaluating efficacy, PK, safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD8871 (AZD8871)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease COPD | Phase 2 | Status: COMPLETED | Results posted: 2019-06-18